WHO/HIV/2005.02
INTERIM WHO
CLINICAL STAGING OF HIV/AIDS
AND
HIV/AIDS CASE DEFINITIONS FOR
SURVEILLANCE
AFRICAN REGION
WHO/HIV/2005.02
INTERIM WHO
CLINICAL STAGING OF HIV/AIDS
AND
HIV/AIDS CASE DEFINITIONS FOR
SURVEILLANCE
AFRICAN REGION
I
© World Health Organization 2005
All rights reserved. Publications of the World Health Organization can be obtained
from Marketing and Dissemination, World Health Organization, 20 Avenue Appia,
1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857;
email: [email protected]). Requests for permission to reproduce or translate
WHO publications – whether for sale or for noncommercial distribution – should be
addressed to Marketing and Dissemination, at the above address (fax: +41 22 791 4806;
email: [email protected]).
The designations employed and the presentation of the material in this publication do
not imply the expression of any opinion whatsoever on the part of the World Health
Organization concerning the legal status of any country, territory, city or area or of its
authorities, or concerning the delimitation of its frontiers or boundaries.
The mention of specific companies or of certain manufacturers’ products does not imply
that they are endorsed or recommended by the World Health Organization in preference
to others of a similar nature that are not mentioned. Errors and omissions excepted, the
names of proprietary products are distinguished by initial capital letters.
All reasonable precautions have been taken by WHO to verify the information contained
in this publication. However, the published material is being distributed without warranty
of any kind, either express or implied. The responsibility for the interpretation and use of
the material lies with the reader. In no event shall the World Health Organization be liable
for damages arising from its use.
Printed in
II
INTERIM WHO CLINICAL STAGING OF HIV/AIDS AND HIV/AIDS CASE DEFINITIONS FOR SURVEILLANCE
AFRICAN REGION
III
9
16
29
41
CONTENTS
Acronyms and Abbreviations __________________________________________________ V
Executive summary __________________________________________________________1
Background ________________________________________________________________2
Revised WHO clinical staging of HIV/AIDS for adults and adolescents _____________________5
Revised WHO clinical staging of HIV/AIDS for infants and children _______________________ 11
Recommendations for implementation ___________________________________________18
Annex 1. WHO clinical staging for adults and adolescents: presumptive and definitive criteria for
recognizing HIV/AIDS-related clinical events _______________________________________20
Annex 2. WHO clinical staging for infants and children: presumptive and definitive criteria for
recognizing HIV/AIDS-related clinical events _______________________________________30
Key References ____________________________________________________________42
IV
INTERIM WHO CLINICAL STAGING OF HIV/AIDS AND HIV/AIDS CASE DEFINITIONS FOR SURVEILLANCE
AFRICAN REGION
ACRONYMS AND ABBREVIATIONS
AFB
AIDS
ART
ARV
BAL
CD4
CDC
CMV
CNS
CRAG
CSF
CT
CXR
DNA
HIV
HSV
IMCI
IRS
JC
LGE
LIP
LP
LRTI
LTB
MOT
MRI
NAT
P24
PCP
PCR
PGL
PLWHA
PML
RF
RVF
RNA
SD
TB
TLC
URTI
WHO
ZN
acid-fast bacilli
acquired immunodeficiency syndrome
antiretroviral therapy
antiretroviral medicine
bronchoalveolar lavage
human T helper cells expressing CD4 antigen (T helper cell)
Centers for Disease Control and Prevention (USA)
cytomegalovirus
central nervous system
cryptococcal antigen
cerebrospinal fluid
computed tomography
chest X-ray
deoxyribonucleic acid
human immunodeficiency virus
herpes simplex virus
integrated management of childhood illness
immune restoration syndrome
Jacob Creutzfeldt (Virus)
linear gingival erythema
lymphoid interstitial pneumonitis
lumbar puncture
lower respiratory tract infection
laryngotracheal bronchitis
mycobacteria other than tuberculosis
magnetic resonance imaging
nucleic acid testing
a soluble antigen produced by HIV
pneumocystis pneumonia
polymerase chain reaction
persistent generalized lymphadenopathy
people living with HIV/AIDS
progressive multifocal leukoencephalopathy
rectal fistula
rectovaginal fistula
ribonucleic acid
standard deviation
tuberculosis
total lymphocyte count
upper respiratory tract infection
World Health Organization
Ziehl-Neelsen (staining method)
V
EXECUTIVE SUMMARY
W
ith a view to facilitating the scale-up of access to antiretroviral therapy
(ART) in the African Region the present document outlines recent
revisions made by WHO to the clinical staging of HIV/AIDS and to
case definitions for HIV/AIDS disease surveillance. These interim guidelines are
based on an international drafting meeting held in Saas Fee in June 2004 and
on recommendations made by experts from African countries at a meeting held
in Nairobi in December of the same year.
The revisions to the clinical staging target professionals ranging from senior
consultants in teaching and referral hospitals to surveillance officers and firstlevel health care providers, all of whom have important roles in caring for
people living with HIV and AIDS (PLWHA), including children. It is proposed that
countries review, adapt and repackage the guidelines as appropriate for specific
tasks at different levels of health service delivery. It is hoped that national HIV/
AIDS programmes in African countries will thus be assisted to develop, revise or
strengthen their ART guidelines, patient monitoring and surveillance efforts.
The interim clinical staging and revised definitions for surveillance are currently
being reviewed in the other WHO regions and will be finalized at a global
meeting to be held in September 2005.
1
INTERIM WHO CLINICAL STAGING OF HIV/AIDS AND HIV/AIDS CASE DEFINITIONS FOR SURVEILLANCE
AFRICAN REGION
BACKGROUND
H
IV/AIDS surveillance is useful for monitoring temporal, geographical and
risk-group trends and for estimating the burden of HIV/AIDS-related
disease. Surveillance definitions were introduced in 1982, and many
different definitions have been used for national and international reporting (1).
The clinical case definitions recommended by WHO in 1985 and revised in 1994
are designed for use in resource-limited settings. They require confirmation of
HIV infection by means of serological testing. The surveillance definitions were
introduced before the widespread use of antiretroviral therapy (ART), which
can restore many patients with severe disease to health, and reverse disease
progression. Surveillance now needs to capture those patients in need of ART.
The WHO clinical staging system for HIV/AIDS, as developed in 1990,
emphasized the use of clinical parameters to guide clinical decision-making for
the management of HIV/AIDS patients. It was designed for use in resourcelimited settings where there was limited access to laboratory services. The WHO
clinical staging system has been widely used in resource-limited countries,
particularly in the African Region, and has proved pragmatic and useful in
facilities at both the first level and the referral level. It was originally hierarchal
in recognition of the relentless progression of HIV infection, with no reversal or
improvement allowed. Unfortunately confusion has occurred with clinical case
definitions for surveillance being used for clinical purposes. The clinical disease
classification system of the Centers for Disease Control and Prevention (CDC)
in the USA which is based on immunological parameters (CD4 counts) clinical
parameters and virological parameters and requires laboratory confirmation of
many clinical events is designed for surveillance purposes, but is frequently used
for clinical management purposes.
In response to the changing landscape of HIV/AIDS, particularly in resourcelimited settings, and specifically to support scale up of anti-retroviral treatment,
revisions and harmonization of the clinical staging and case definitions for
surveillance are required. For this reason, WHO in collaboration with CDC, held
two expert consultative meetings, in June 2004 in Saas Fe, Switzerland and in
December 2004 in Nairobi, Kenya to review and revise the 1994 WHO clinical
staging system and AIDS case definitions. The revisions made were based upon
the best available evidence or, where evidence was inconclusive or unavailable,
on the balance of expert opinion. This present document describes the interim
WHO clinical staging system and case definitions as agreed during the second
meeting, held in Nairobi.
2
The revisions are also designed to reflect that with the use of ART HIV is a
chronic disease. ART changes the prognosis and can reverse the inevitable
progression through the clinical stages.
The revisions were designed to strengthen clinical staging and the AIDS case
definitions for both adults and children, and to simplify and standardize
definitions for use by a cross-section of health providers, programme managers
and surveillance officers. They were also intended to harmonize paediatric
and adult clinical staging and AIDS case definitions so as to improve patient
management, patient monitoring and surveillance efforts.
The aims of the proposed revisions were to:
◗
provide greater consistency between the adult and paediatric staging
systems;
◗
harmonize clinical case definitions and surveillance definitions;
◗
provide clinical and immunological staging for adults and children
based upon the degree of immunocompromise and prognosis, but that
facilitates follow up care;
◗
provide guidance on the care of children aged under 18 months, in
whom persisting maternal antibodies make it difficult to definitively
diagnose HIV infection if virological or P24 antigen testing is not readily
available;
◗
facilitate the use of the clinical staging system and HIV/AIDS case
definitions by non-specialist and non-paediatric health care workers at
the basic level and in peripheral health care facilities;
◗
assist with clinical decision-making, including decisions on starting,
substituting, switching and stopping ART, and with routine follow up
of patients on treatment;
◗
permit the inclusion of laboratory testing, especially CD4 count, where
available, so as to guide prognosis and assist in determining the need
for ART and other therapies;
◗
provide surveillance definitions for advanced stages of HIV infection
which reflect disease requiring ART either immediately or in the near
future.
The clinical staging is presented in two summary tables (1 and 4). Table 1 is to
be is used for those who are 15a years and above for whom there is confirmed
laboratory evidence of HIV infection. Table 4 concerns infants and children
aged under 15 years with confirmed laboratory evidence of HIV infection. An
a
3
The cut off age of 15 years is applied as this is the usual cut off for surveillance definitions.
INTERIM WHO CLINICAL STAGING OF HIV/AIDS AND HIV/AIDS CASE DEFINITIONS FOR SURVEILLANCE
AFRICAN REGION
additional classification for presumptive diagnosis of clinical stage 4 (severe HIV
infection) in infants under 18 months is also available for use in situations where
definitive diagnosis of HIV infection is not readily available.
Clinical events are categorized as those where a presumptive clinical
diagnosis may be made (conditions that can be diagnosed clinically or with basic
laboratory tests) and those where a definitive diagnosis may be made (for
conditions requiring more complex and sophisticated laboratory investigations).
Also given are explanatory notes, proposed immunological staging categories,
implications for criteria to initiate ART and proposed harmonized definitions of
advanced HIV/AIDS for the purposes of surveillance. Clinical staging needs to
be performed at determination or confirmation of HIV infection, and on entry to
clinical care (pre-ART) to help guide ART and care related decisions. Assessment
of clinical stage at each clinical visit also provides useful information on current
clinical status, and can guide clinical decision making. National guidelines for
the clinical management of HIV/AIDS can be modified on this basis.
Annex 1 addresses issues related to the recognition and diagnosis of clinical
events in adults and adolescents, and key decisions related to clinical events
pre-ART and while on ART; Annex 2 does the same for infants and children.
4
REVISED WHO CLINICAL STAGING OF HIV/AIDS
FOR ADULTS AND ADOLESCENTS
(Interim African Region version for persons aged 15 years or more with positive HIV antibody test or
other laboratory evidence of HIV infection) b
TABLE 1. REVISED WHO CLINICAL STAGING OF HIV/AIDS FOR ADULTS AND ADOLESCENTS
Primary HIV infection
Asymptomatic
Acute retroviral syndrome
Clinical stage 1
Asymptomatic
Persistent generalized lymphadenopathy (PGL)
Clinical stage 2
Moderate unexplained weight loss (<10% of presumed or measured body weight)
Recurrent respiratory tract infections (RTIs, sinusitis, bronchitis, otitis media, pharyngitis)
Herpes zoster
Angular cheilitis
Recurrent oral ulcerations
Papular pruritic eruptions
Seborrhoeic dermatitis
Fungal nail infections of fingers
Clinical stage 3
Conditions where a presumptive diagnosis can be made on the basis of clinical
signs or simple investigations
Severe weight loss (>10% of presumed or measured body weight)
Unexplained chronic diarrhoea for longer than one month
Unexplained persistent fever (intermittent or constant for longer than one month)
Oral candidiasis
Oral hairy leukoplakia
Pulmonary tuberculosis (TB) diagnosed in last two years
Severe presumed bacterial infections (e.g. pneumonia, empyema, pyomyositis, bone or
joint infection, meningitis, bacteraemia)
Acute necrotizing ulcerative stomatitis, gingivitis or periodontitis
Conditions where confirmatory diagnostic testing is necessary
Unexplained anaemia (< 8 g/dl), and or neutropenia (<500/mm3) and or
thrombocytopenia (<50 000/ mm3) for more than one month
b
All clinical events or conditions referred to are described in the Annexes. The UN defines
adolescents as persons aged 10−19 years but, in the present document, the category of
adults and adolescents comprises people aged 15 years and over for surveillance purposes.
5
INTERIM WHO CLINICAL STAGING OF HIV/AIDS AND HIV/AIDS CASE DEFINITIONS FOR SURVEILLANCE
AFRICAN REGION
Clinical stage 4
Conditions where a presumptive diagnosis can be made on the basis of clinical
signs or simple investigations
HIV wasting syndrome
Pneumocystis pneumonia
Recurrent severe or radiological bacterial pneumonia
Chronic herpes simplex infection (orolabial, genital or anorectal of more than one month’s
duration)
Oesophageal candidiasis
Extrapulmonary TB
Kaposi’s sarcoma
Central nervous system (CNS) toxoplasmosis
HIV encephalopathy
Conditions where confirmatory diagnostic testing is necessary:
Extrapulmonary cryptococcosis including meningitis
Disseminated non-tuberculous mycobacteria infection
Progressive multifocal leukoencephalopathy (PML)
Candida of trachea, bronchi or lungs
Cryptosporidiosis
Isosporiasis
Visceral herpes simplex infection
Cytomegalovirus (CMV) infection (retinitis or of an organ other than liver, spleen or lymph nodes)
Any disseminated mycosis (e.g. histoplasmosis, coccidiomycosis, penicilliosis)
Recurrent non-typhoidal salmonella septicaemia
Lymphoma (cerebral or B cell non-Hodgkin)
Invasive cervical carcinoma
Visceral leishmaniasis
6
EXPLANATORY NOTES
The 2005 revised clinical staging system for adults and adolescents is designed to:
◗
be used where HIV infection is confirmed by HIV antibody or virological
testing;
◗
harmonize with newly proposed immunological criteria
◗
harmonize with revised HIV/AIDS surveillance definitions
For clinical management purposes it is designed to:
◗
be used for assessment at baseline or entry into HIV care to guide
decisions on when to start cotrimoxazole prophylaxis, start ART and
other HIV related interventions;
◗
provide simple guidance to assist clinical care providers on when to start,
substitute, switch or stop ART in HIV-infected adults and adolescents,
or to trigger referral as outlined in the WHO ART guidelines for a public
health approach(2);
◗
be used to assess current clinical status of individuals in HIV care, either
on or off ART;
◗
encourage clinical care providers to offer diagnostic testing for HIV in
adults and adolescents exhibiting the clinical events suggestive of HIV
disease;
◗
prompt urgent offer of HIV diagnostic testing for stage 3 or stage
4 events either on site, or by referral for testing to a site where
immediate assessment by HIV care providers able to initiate ART can be
performed;
◗
be used to guide clinicians in assessing the response to ART, particularly
where viral load and/or CD4 counts or percentages are not widely or
easily available (new or recurrent stage 4 events may suggest failure
of response to treatment; new or recurrent stage 2 or stage 3 events
may suggest an inadequate response to treatment, potentially because
of poor adherence; however further evidence is required in order to
determine the significance of staging events once ART has commenced.
Clinical events in the first three months after ART has begun may be
caused by immune restoration syndrome (IRS) rather than a poor
response to ART).
Note: Total lymphocyte count (TLC) is not currently recommended for
monitoring therapy.
7
INTERIM WHO CLINICAL STAGING OF HIV/AIDS AND HIV/AIDS CASE DEFINITIONS FOR SURVEILLANCE
AFRICAN REGION
Annex 1 provides further descriptions of each clinical event and their diagnosis
clinically or with basic laboratory or radiological investigations (presumptive
diagnosis) and on requirements for more sophisticated investigations (definitive
diagnosis).
For surveillance purposes it is designed to:
◗
classify disease in a progressive sequence from least to most severe and
remains hierarchical (with only the first stage 3 or stage 4 clinical event
requiring notification);
◗
be used with reference to current clinical events, meaning those that
have been diagnosed or are currently being managed;
◗
be considered in relation to previous clinical events, such as reported
TB, severe pneumonia, PCP or other conditions; this is retrospective
clinical staging for surveillance.
IMMUNOLOGICAL STAGING OF HIV INFECTION
Clinical staging can be used effectively without access to CD4 or other
laboratory testing. However, CD4 testing is useful for determining the degree
of immunocompromise, and where CD4 facilities are available they should be
used to support and reinforce clinical decision-making. Data on CD4 levels are
not a prerequisite for starting ART and should only be used in conjunction with
consideration of the clinical stage. Table 2 presents CD4 levels in relation to the
severity of immunosuppression.
For clinical purposes long term prognosis has been shown to be related to the
nadir or lowest-ever value of CD4. It should be noted that the immunological
staging of disease reverses with successful ART.
TABLE 2. CD4 LEVELS IN RELATION TO THE SEVERITY OF IMMUNOSUPPRESSION
Not significant immunosuppression
>500/mm3
Mild immunosuppression
350 − 499/mm3
Advanced immunosuppression
200 −349/mm3
Severe immunosuppression
<200/mm3
8
IMPLICATIONS FOR CLINICAL AND IMMUNOLOGICAL CRITERIA FOR
INITIATING ART IN ADULTS AND ADOLESCENTS
There is strong evidence for the clinical benefit of ART in adults with advanced
HIV/AIDS as determined clinically or immunologically. The precise clinical and
or immunological criteria for initiating ART is usually outlined in national
treatment guidelines. Existing WHO recommendations are provided on a
WHO web site (2).
TABLE 3. CLINICAL
AND IMMUNOLOGICAL CRITERIA FOR INITIATING
ART
IN ADULTS
AND ADOLESCENTS
Clinical stage
ART
4
Treat.
3
Consider treatment: CD4, if available, can guide
the urgency with which ART should be started.
1 or 2
Only if CD4 <200/mm3.
CD4 can be used to monitor responses to treatment, although they are not
essential. Absolute CD4 values also fluctuate with intercurrent illness and
with physiological and test variability, so the trend over two or three repeated
measurements is usually more informative than individual values. Note: that
during the course of acute HIV infection the CD4 count may reach very low
levels and then recover.
9
INTERIM WHO CLINICAL STAGING OF HIV/AIDS AND HIV/AIDS CASE DEFINITIONS FOR SURVEILLANCE
AFRICAN REGION
PROPOSED HARMONIZED DEFINITIONS OF ADVANCED
HIV/AIDS DISEASE FOR SURVEILLANCE IN
ADULTS AND ADOLESCENTS
AIDS case definitions first developed in 1982 were primarily designed as an
epidemiological tool for surveillance purposes. Various revisions over the next
two decades led to inclusion of clinical and laboratory criteria to the surveillance
definitions. WHO introduced a clinical case definition for surveillance in 1985,
and revised this in 1986 and 1994 to include serological testing for HIV.
‘AIDS’ as a term has also been used to describe the various clinical syndromes,
specific opportunistic infections or malignancies that occur with HIV infection
and signal those in whom advanced HIV infection has occurred. There has been
confusion between surveillance definitions and clinical staging definitions. These
guidelines seek to harmonize both. In the present context of scaling up ART the
purpose of surveillance is to monitor the burden of advanced HIV disease and
allow estimates of the number of people who require or may shortly require
ART.
Including a CD4 threshold in surveillance definitions specifies the level at which
advanced HIV related immunosuppression is deemed to have occurred and from
which intervention with ART is immediately or soon needed to offset disease
progression. For surveillance purposes once the clinical OR immunological trigger
event has occurred the patient should be captured only once in surveillance
data, regardless of ART or other treatment interventions or outcomes.
BOX 1.
ADVANCED HIV/AIDS DISEASE DEFINITIONS FOR SURVEILLANCE
Any clinical stage 3 or stage 4 disease
or,
where CD4 is availablec, any clinical stage and CD4 <350/mm3.
c
CD4 based reporting remains optional
10
REVISED WHO CLINICAL STAGING OF HIV/AIDS FOR
INFANTS AND CHILDREN
(INTE RIM AFRICAN RE GION VE RSION FOR P E RSONS AGE D UND E R 15 YE ARS W ITH
HIV INFE CTION : HIV ANTIB OD Y IF AGE D 18 M ONTH S AND
AB OVE ; VIROLOGICAL OR P24 ANTIGE N TE STING IF AGE D UND E R 18 M ONTH S ) D
CON fiRM E D LAB ORATORY E VID E NCE OF
TABLE 4.
REVISED WHO CLINICAL STAGING OF HIV/AIDS FOR INFANTS AND CHILDREN
Clinical Stage 1
Asymptomatic
PGL
Clinical Stage 2
Hepatosplenomegaly
Papular pruritic eruptions
Seborrhoeic dermatitis
Extensive human papilloma virus infection
Extensive molluscum contagiosum
Fungal nail infections
Recurrent oral ulcerations
Lineal gingival erythema (LGE)
Angular cheilitis
Parotid enlargement
Herpes zoster
Recurrent or chronic RTIs (otitis media, otorrhoea, sinusitis)
Clinical Stage 3
Conditions where a presumptive diagnosis can be made on the basis of clinical
signs or simple investigations
Moderate unexplained malnutrition not adequately responding to standard therapy
Unexplained persistent diarrhoea (14 days or more )
Unexplained persistent fever (intermittent or constant, for longer than one month)
Oral candidiasis (outside neonatal period )
Oral hairy leukoplakia
Acute necrotizing ulcerative gingivitis/periodontitis
Pulmonary TB
Severe recurrent presumed bacterial pneumonia
d
11
All clinical events or conditions referred to are described in the Annexes.
INTERIM WHO CLINICAL STAGING OF HIV/AIDS AND HIV/AIDS CASE DEFINITIONS FOR SURVEILLANCE
AFRICAN REGION
Conditions where confirmatory diagnostic testing is necessary
Chronic HIV-associated lung disease including brochiectasis
Lymphoid interstitial pneumonitis (LIP)
Unexplained anaemia (<8g/dl), and or neutropenia (<1000/mm3) and or
thrombocytopenia (<50 000/ mm3) for more than one month
Clinical Stage 4
Conditions where a presumptive diagnosis can be made on the basis of clinical
signs or simple investigations
Unexplained severe wasting or severe malnutrition not adequately responding to standard
therapy
Pneumocystis pneumonia
Recurrent severe presumed bacterial infections (e.g. empyema, pyomyositis, bone or joint
infection, meningitis, but excluding pneumonia)
Chronic herpes simplex infection; (orolabial or cutaneous of more than one month’s duration)
Extrapulmonary TB
Kaposi’s sarcoma
Oesophageal candidiasis
CNS toxoplasmosis (outside the neonatal period)
HIV encephalopathy
Conditions where confirmatory diagnostic testing is necessary
CMV infection (CMV retinitis or infection of organs other than liver, spleen or lymph nodes;
onset at age one month or more)
Extrapulmonary cryptococcosis including meningitis
Any disseminated endemic mycosis (e.g. extrapulmonary histoplasmosis, coccidiomycosis,
penicilliosis)
Cryptosporidiosis
Isosporiasis
Disseminated non-tuberculous mycobacteria infection
Candida of trachea, bronchi or lungs
Visceral herpes simplex infection
Acquired HIV associated rectal fistula
Cerebral or B cell non-Hodgkin lymphoma
Progressive multifocal leukoencephalopathy (PML)
HIV-associated cardiomyopathy or HIV-associated nephropathy
12
PRESUMPTIVE DIAGNOSIS OF CLINICAL STAGE 4 HIV IN
CHILDREN AGED UNDER 18 MONTHS
The presumptive diagnosis is designed for use where access to confirmatory
diagnostic testing for HIV infection by means of virological testing (usually nucleic
acid testing, NAT) or P24 antigen testing for infants and children aged under 18
months is not readily available. It is not recommended for use by clinical care
providers who are not trained in ART or experienced in HIV care. It should
be accompanied by immediate efforts to confirm the HIV diagnosis with the best
nationally or locally available test for age. Presumptive diagnosis of clinical stage 4
disease suggests severe immunosuppression, and ART is indicated.
BOX 2. PRESUMPTIVE CLINICAL STAGE 4 IN INFANTS AND CHILDREN AGED UNDER
18 MONTHS WHERE VIROLOGICAL CONFIRMATION OF HIV INFECTION IS NOT AVAILABLE
A presumptive diagnosis of stage 4 clinical disease
should be made if:
An infant is HIV-antibody positive (ELISA or rapid test), aged under 18 months
and symptomatic with two or more of the following:
+/– oral thrush;
+/– severe pneumonia e
+/– severe wasting/malnutrition
+/– severe sepsis f
CD4 values, where available, may be used to guide decision-making; CD4
percentages below 25% require ART
Other factors that support the diagnosis of clinical stage 4 HIV infection in an
HIV-seropositive infant are:
• recent HIV related maternal death
• advanced HIV disease in the mother.
Confirmation of the diagnosis of HIV infection should be sought as soon as
possible.
EXPLANATORY NOTES
The 2005 revised clinical staging system for infants and children is designed to:
e
f
13
◗
be used where HIV infection is confirmed by HIV antibody or virological
testing;
◗
harmonize with newly proposed immunological criteria
◗
harmonize with revised HIV/AIDS surveillance definitions
Pneumonia requiring oxygen.
Requiring intravenous therapy.
INTERIM WHO CLINICAL STAGING OF HIV/AIDS AND HIV/AIDS CASE DEFINITIONS FOR SURVEILLANCE
AFRICAN REGION
For clinical management purposes it is designed to:
◗
be used for assessment at baseline or entry into HIV care to guide
decisions on when to start cotrimoxazole prophylaxis, start ART and
other HIV related interventions;
◗
provide simple guidance to assist clinical care providers on when to
start, substitute, switch or stop ART in HIV-infected children, or to
trigger referral as outlined in the WHO ART guidelines for a public
health approach(2);
◗
be used to assess current clinical status of children in HIV care, either on
or off ART;
◗
encourage clinical care providers to offer HIV diagnostic testing in infants
and children exhibiting clinical events suggestive of HIV disease;
◗
prompt urgent referral for diagnostic HIV testing and assessment for all
Stage 3 or stage 4 events in children where HIV status is unknown or a
child is known to be HIV exposed;
◗
be used to guide clinicians in assessing the response to ART, particularly
where viral load and/or CD4 counts or percentages are not widely
or easily available (however, further evidence is required in order to
determine the significance of staging events once ART has been started;
new or recurrent stage 4 events may suggest a failure of response to
treatment; new or recurrent stage 2 or stage 3 events may suggest
an inadequate response to treatment, potentially attributable to poor
adherence); note that clinical events in the first three months after
starting ART may be attributable to IRS rather than a poor response to
ART; this is reported less commonly in children;
Note: Total lymphocyte count (TLC) is not currently recommended for
monitoring therapy.
Annex 2 provides further descriptions of each clinical event and their diagnosis
clinically or with basic laboratory or radiological investigations (presumptive
diagnosis) and on requirements for more sophisticated investigations (definitive
diagnosis).
For surveillance purposes it is designed to;
◗
classify disease in a progressive sequence from least to most severe and
remains hierarchical (with only the first stage 3 or stage 4 clinical event
requiring notification);
◗
be used with reference to current clinical events, meaning those that
have been diagnosed or are currently being managed;
14
◗
be considered in relation to previous clinical events, such as reported
TB, severe pneumonia, PCP or other conditions; this is retrospective
clinical staging for surveillance.
IMMUNOLOGICAL CATEGORIES FOR PAEDIATRIC
HIV INFECTION
Immunological staging for children is also possible. The absolute CD4 count
and the percentage values in healthy infants who are not infected with HIV
are considerably higher than those observed in uninfected adults, and slowly
decline to adult values by the age of 6 years. In considering absolute counts
or percentages, therefore, age must be taken into account as a variable. The
absolute CD4 count associated with a specific level of immunosuppression tend
to change with age, whereas the CD4 percentage related to immunological
damage does not vary as much. Currently, therefore, the measurement of
the CD4 percentage is recommended in younger children. CD4 testing is not
essential for the initiation of ART, and should only be used in conjunction with
the clinical stage. As for adults, immunological staging assists clinical decisionmaking and provides a link with monitoring and surveillance definitions. It is
usually reversed by successful ART.
TABLE 5.
CD4 LEVELS IN RELATION TO THE SEVERITY OF IMMUNOSUPPRESSION
Age
Up to 12
months
13-59
months
5 years or
over
>35%
>25%
>500/mm3
Mild immunosuppression
25−34%
20−24%
350−499/mm3
Advanced immunosuppression
20−24%
15−19%
200−349/mm3
<20%
<15%
<200/mm3
Immune status
Not significant immunosuppression
Severe immunosuppression
15
INTERIM WHO CLINICAL STAGING OF HIV/AIDS AND HIV/AIDS CASE DEFINITIONS FOR SURVEILLANCE
AFRICAN REGION
IMPLICATIONS FOR CLINICAL AND IMMUNOLOGICAL
CRITERIA FOR INITIATING ART
Although there are concerns about the early use of ART in asymptomatic infants,
all children with stage 3 or stage 4 disease (advanced HIV defined clinically)
should start ART following discussion with their families. There is very strong
evidence for the clinical benefit of ART in children with advanced HIV/AIDS. For
older children some clinical conditions, e.g. LIP, appear to have a more stable
clinical course, although there are few data on cohorts from African settings.
Because of the revisions in clinical staging these recommendations should
replace those provided in the 2003 WHO reference guide (2).
TABLE 6.
CLINICAL AND IMMUNOLOGICAL CRITERIA FOR INITIATING ART IN
INFANTS AND CHILDREN
Clinical stages
ART
4
Treat.
Presumptive stage 4
Treat.
3
Consider treatment for all ages. Children aged
under 2 years usually require ART.
CD4 %, if available should be used to guide
decisions on ART.
Usually only where CD4 available.
1 and 2
Under 12 months: CD4 % < 20
13-59 months : CD4 % < 15
5 years or over CD4 <200/mm3
Note: co-trimoxazole prophylaxis should be given to all HIV-exposed infants
and children until HIV infection is excluded and to all HIV-infected infants and
children
CD4 can be used to monitor responses to treatment, although it is not essential.
Absolute CD4 values also fluctuate with intercurrent illness and with physiological
and test variability, so the trend over two or three repeated measurements is
usually more informative than individual values.
16
PROPOSED HARMONIZED DEFINITIONS OF ADVANCED
HIV/AIDS DISEASE FOR SURVEILLANCE IN
CHILDREN AGED UNDER 15 YEARS
The surveillance of paediatric HIV/AIDS can provide estimates of the number
of infants and children who require or may shortly require ART. AIDS case
definitions for surveillance have until recently only been provided by CDC and
include laboratory criteria. There has been confusion between surveillance
definitions and clinical staging definitions.
These guidelines propose age-related clinical and immunological case definitions
of advanced HIV/AIDS disease in infants and children for surveillance purposes.
Age-related definitions are required because of the age-related changes in
immunological markers. Advanced HIV disease for surveillance purposes should
be reported only once for each individual.
BOX 3.
ADVANCED HIV/AIDS DISEASE DEFINITIONS FOR SURVEILLANCE FOR
INFANTS AND CHILDREN
Clinical stage 3 or stage 4 disease at any age
or
where CD4 is availableg, any clinical stage with
• CD4 % <25% in children aged under 12 months
• CD4 % <20% in children aged 12 -59 months
• CD4 <350/mm3 in children aged 5 years and above
g
17
CD4 based reporting remains optional
INTERIM WHO CLINICAL STAGING OF HIV/AIDS AND HIV/AIDS CASE DEFINITIONS FOR SURVEILLANCE
AFRICAN REGION
RECOMMENDATIONS FOR IMPLEMENTATION
The following recommendations concern the use of the revised clinical staging
and HIV/AIDS case definitions for clinical management and case-reporting.
◗
The revised clinical staging should be used to update and strengthen
national guidelines so as to ensure that they provide clear guidance on
which clinical and immunological stages require or are eligible for cotrimoxazole prophylaxis and ART treatment and support patient follow up.
◗
All infants, children, adolescents and adults with clinical stage 3 or stage
4 disease should be reported as having advanced HIV/AIDS disease. Such
case reports can be used to calculate the burden of HIV/AIDS which
immediately requires or will soon require ART. HIV/AIDS reporting for
surveillance should preserve patient confidentiality in accordance with
existing national or international recommendations.
◗
National HIV/AIDS programmes should be encouraged to support
CD4-based HIV/AIDS case-reporting for surveillance.
The following additional recommendations concern actions facilitating the
use of the interim clinical staging system and HIV/AIDS case definitions for
surveillance.
Actions at the global and regional level:
◗
At the global level, WHO should publish details of the new HIV/AIDS
clinical staging.
◗
At the global level, WHO should develop and disseminate guidelines
on the use of the revised HIV clinical staging system and of the revised
case definitions.
◗
At the regional level, WHO should organize intercountry meetings in
order to introduce the revisions and to encourage rapid implementation
in countries.
◗
WHO and CDC should incorporate the proposed revisions to
surveillance definitions into surveillance training materials that are
under development.
◗
WHO and CDC should provide technical support for the adoption and
scaling-up for implementation of these revisions in countries.
◗
WHO and CDC should provide technical support for the development
of systems for reporting AIDS-related deaths.
◗
WHO and CDC will hold a meeting during the fourth quarter of 2006
in order to review and update the clinical staging system and case
definitions.
18
Actions at the national level
19
◗
Ministries of health and their partners should organize national
consensus meetings on the proposed revisions, and should adapt and
repackage the regional guidelines in accordance with existing national
specifications in a way that is appropriate for use at different levels of
health service delivery.
◗
Ministries of health should integrate the proposed revisions into
existing guidelines and procedures for HIV/AIDS clinical management
and HIV/AIDS case-reporting.
◗
Ministries of health should organize in-country training in order to build
capacity for the implementation of the revisions, including integration
into the curricula of relevant professional and non-professional training
institutions.
◗
Ministries of health should produce simplified wall charts, laminated
desk-top guides, pocket guides and other materials facilitating the use
of the recommended revisions.
◗
Ministries of health should establish systems for HIV/AIDS reporting in
children at a few sentinel sites where children are seen to improve and
strengthen the provision of information on children with HIV/AIDS.
◗
Ministries of health should ensure that reliable systems are in place for
reporting AIDS-related deaths.
INTERIM WHO CLINICAL STAGING OF HIV/AIDS AND HIV/AIDS CASE DEFINITIONS FOR SURVEILLANCE
AFRICAN REGION
ANNEX 1.
WHO CLINICAL STAGING FOR ADULTS AND ADOLESCENTS:
PRESUMPTIVE AND DEFINITIVE CRITERIA FOR RECOGNIZING
HIV/AIDS-RELATED CLINICAL EVENTS
(For use in adults and adolescents aged 15 years and above with laboratory evidence of HIV infection.)
Clinical event
Presumptive diagnosis
Definitive diagnosis
Primary HIV infection
Asymptomatic
Acute retroviral syndrome
Detectable core P24
antigen and high blood HIV
Acute febrile illness 2−4 weeks
RNA, profound temporary
post-exposure, often with
lymphopenia and other
lymphadenopathy, pharyngitis
transient blood abnormalities
and skin manifestations.
may occur. Not usually HIV
antibody-positive until after
symptoms.
Seroconversion from HIV Abnegative to Ab-positive.
Clinical Stage 1
Asymptomatic
No symptoms reported and no
signs on examination.
Not required.
Persistent generalized
lymphadenopathy
(PGL)
Swollen or enlarged lymph
nodes >1 cm, in two or more
non-contiguous sites, excluding
inguinal nodes, in absence of
known cause.
Not required but can be
confirmed by histology
(germinal centre hyperplasia,
lymph node structure
preserved).
Moderate unexplained weight
loss (<10% of presumed or
measured body weight)
Reported weight loss but no
obvious thinning of face or
body.
Confirmed by documented
weight loss.
Recurrent presumed bacterial
RTI
(two or more in any six-month
period)
Symptom complex, e.g.
unilateral face pain with
nasal discharge (sinusitis) or
painful swollen eardrum (otitis
media), cough with purulent
sputum (bronchitis), sore throat
(pharyngitis). Two or more
documented occurrences of
antibiotic- responsive URTI.
Not required but may be
confirmed by laboratory studies
where available, e.g. culture of
suitable body fluid.
Clinical Stage 2
20
Clinical event
Presumptive diagnosis
Definitive diagnosis
Herpes zoster
Painful rash of small fluidNot required.
filled blisters in distribution
of a nerve supply, can be
haemorrhagic on erythematous
background, and does not
cross midline. Current or in
the last two years. Severe or
frequently recurrent herpes
zoster is usually associated
with more advanced HIV
disease.
Angular cheilitis
Splits or cracks on lips at
the angle of the mouth with
depigmentation, usually
responds to antifungal
treatment but may recur.
Also common in nutritional
deficiency, e.g. of B vitamins.
Recurrent oral ulcerations
occurring twice or more in six
months
Aphthous ulceration,
Not required.
typically with a halo of
inflammation and a yellow-grey
pseudomembrane.
Papular pruritic eruptions
Not required.
Papular pruritic vesicular
lesions. Also common in
uninfected adults.
Note: scabies and obvious
insect bites should be excluded.
Seborrhoeic dermatitis
Itchy scaly skin condition,
particularly affecting scalp,
face, upper trunk and
perineum. Also common in
uninfected adults.
Not required.
Not required.
Fungal nail infections of fingers Fungal paronychia (painful
Not required but confirmed by
red and swollen nail bed) or
culture of nail scrapings.
onycholysis (separation of the
nail from the nail bed) of the
fingernails. Also common in
uninfected adults. Proximal
white subungual onchomycosis
is uncommon without
immunodeficiency.
21
INTERIM WHO CLINICAL STAGING OF HIV/AIDS AND HIV/AIDS CASE DEFINITIONS FOR SURVEILLANCE
AFRICAN REGION
Clinical Stage 3
Clinical event
Presumptive diagnosis
Definitive diagnosis
Severe unexplained weight loss Reported weight loss without
(more than 10% of presumed trying, and noticeable thinning
or measured body weight)
of face, waist and extremities.
Documented loss of more than
10% of body weight.
Unexplained chronic diarrhoea
for longer than one month
Chronic diarrhoea (loose or
watery stools three or more
times daily) reported for longer
than one month.
Not required but confirmed if
three or more stools observed
and documented as unformed,
and two or more stool tests
reveal no pathogens on
microscopy and culture and no
faecal leukocytes.
Unexplained persistent fever
(intermittent or constant and
for longer than one month)
Reports of fever or night
sweats for more than one
month, either intermittent or
constant with reported lack
of response to antibiotics or
antimalarials. No other obvious
foci of disease reported or
found on examination. Malaria
must be excluded in malarious
areas.
Not required but confirmed if
documented fever >37.5 °C
with negative blood culture,
negative Ziehl-Nielsen (ZN)
stain, negative malaria slide,
normal or unchanged chest Xray (CXR) and no other obvious
foci of disease.
Oral candidiasis
Persistant creamy white
Not required.
to yellow soft small
plaques on red or normally
coloured mucosa which
can often be scraped off
(pseudomembranous), or red
patches on tongue, palate or
lining of mouth, usually painful
or tender (erythematous
form), not responding to local
antifungal treatment.
Oral hairy leukoplakia
Fine small linear patches on
lateral borders of the tongue,
generally bilaterally, which do
not scrape off.
Not required.
22
Clinical event
Pulmonary TB
(current or in last two years)
Presumptive diagnosis
Definitive diagnosis
Chronic (symptoms lasting
Not required but confirmed by
three or more weeks)
positive sputum culture.
productive cough, haemoptysis,
shortness of breath, weight
loss, fever, night sweats
and fatigue, no resolution
of symptoms with standard
broad-spectrum antibiotics,
positive ZN stain.
Response to standard anti-TB
treatment in one month.
Note: TB diagnosis and
treatment should follow
national or international
guidelines.
CD4 should be used where
possible to guide therapy; very
low CD4 may require urgent
ART.
Severe presumed bacterial
infection (e.g. pneumonia,
meningitis, empyema,
pyomyositis, bone or joint
infection, bacteraemia )
Fever accompanied by specific Not required but confirmed
symptoms or signs that localize by bacteria isolated from
infection, and response to
appropriate clinical specimens.
antibiotic.
Acute necrotizing ulcerative
gingivitis or necrotizing
ulcerative periodontitis
Severe pain, ulcerated gingival
papillae, loosening of teeth,
spontaneous bleeding, bad
odour, and rapid loss of bone
and/or soft tissue.
Unexplained anaemia (<8g/dl), No presumptive clinical
neutropenia (<1000/mm3 ) or diagnosis.
thrombocytopenia(<50000/mm3)
for more than one month
Not required.
Diagnosed on laboratory
testing and not explained by
other non-HIV conditions. Not
responding to standard therapy
with haematinics, antimalarials
or anthelmintics as outlined
in relevant national treatment
guidelines, WHO guidelines or
other relevant guidelines.
Clinical Stage 4
23
INTERIM WHO CLINICAL STAGING OF HIV/AIDS AND HIV/AIDS CASE DEFINITIONS FOR SURVEILLANCE
AFRICAN REGION
Clinical event
HIV wasting syndrome
Presumptive diagnosis
Unexplained weight loss
greater than 10% of body
weight and visible thinning of
face, waist and extremities;
plus
either unexplained chronic
diarrhoea (lasting more than
one month)
or
unexplained prolonged or
intermittent fever for one
month or more.
Pneumocystis pneumonia
Dry cough, progressive
shortness of breath, especially
on exertion, with cyanosis,
tachypnoea and fever,
response to high-dose cotrimoxazole +/– prednisolone.
Bilateral crepitations on
auscultation with or without
reduced air entry.
Definitive diagnosis
Confirmed by documented
weight loss without trying;
plus
documented unformed stools
negative for pathogens;
negative for modified ZN;
or
Documented temperature of
37.5 °C or more on occasions
with no obvious foci of disease,
negative blood culture, negative
malaria slide and normal or
unchanged CXR.
Not required but confirmed by:
microscopy of induced sputum
or bronchoalveolar lavage
(BAL), or histology of lung
tissue.
CXR may show typical bilateral
interstitial infiltrate with bat
wing appearance.
Recurrent severe or radiological Two episodes of fever, wet
bacterial pneumonia (two or
cough, fast and difficult
more episodes within one year) breathing and chest pain.
Consolidation on clinical
examination and CXR.
Response to antibiotics.
Not required but confirmed
Chronic herpes simplex virus
(HSV) infection (orolabial,
genital or anorectal of more
than one month, or visceral of
any duration)
Not required for mucocutanoues
HSV but required for visceral
HSV. Suggestive symptoms of
organ damage, e.g. bronchitis,
pneumonitis, oesophagitis,
colitis, encephalitis, supported
by histology or culture.
Severe and progressive painful
orolabial, genital, or anorectal
lesions caused by recurrent
HSV infection reported for
more than one month. History
of previous episodes. Scarring
from previous episodes may be
evident.
by culture or antigen test from
appropriate specimen.
24
Clinical event
Presumptive diagnosis
Oesophageal candidiasis
Chest pain and dysphagia
(difficulty in swallowing),
odynophagia (pain on
swallowing food and fluids),
or retrosternal pain worse on
swallowing (food and fluids)
+/– oral Candida. Responds
to antifungal treatment.
Not required but confirmed by
macroscopic appearance at
endoscopy or bronchoscopy,
microscopy or histology.
Extrapulmonary/disseminated
TB
Systemic illness usually with
prolonged fever, night sweats,
weakness and weight loss.
Not required but confirmed by
acid-fast bacilli (AFBs) seen in
microscopy of cerebrospinal
fluid (CSF), effusion, lymph
node aspirate, urine, etc.
Clinical features of organs
involved, e.g. focal
lymphadenopathy, cold
abscess, sterile pyuria,
pericarditis, ascites, pleural
effusion, meningitis, arthritis,
orchitis, lupus vulgaris.
CXR may reveal diffuse
uniformly distributed small
miliary shadows
Kaposi’s sarcoma
25
Definitive diagnosis
Mycobacteria TB isolated from
blood culture or any appropriate
specimen except sputum or
BAL.
Histology (e.g. pleural or
pericardial biopsy).
CXR may show interstitial
infiltrates.
Response to standard anti-TB
treatment in one month.
Lymphocytic CSF with
typical abnormalities, no
bacterial growth and negative
cryptococcal antigen (CRAG).
Typical appearance in skin
or oropharynx of persistent,
initially flat, patches with a
pink or blood-bruise colour,
skin lesions that usually
develop into nodules. Can
be confused clinically with
bacillary angiomatosis, nonHodgkin lymphoma and
cutaneous fungal or bacterial
infections.
Not required but may be
confirmed by :
• typical red-purple lesions
seen on bronchoscopy or
endoscopy;
• dense masses in lymph nodes,
viscera or lungs by palpation
or radiology;
• histology.
INTERIM WHO CLINICAL STAGING OF HIV/AIDS AND HIV/AIDS CASE DEFINITIONS FOR SURVEILLANCE
AFRICAN REGION
Clinical event
Presumptive diagnosis
CMV (retinitis or CMV infection Retinitis only.
of an organ other than liver,
CMV retinitis may be diagnosed
spleen or lymph nodes)
by experienced clinicians.
Progressive floaters in field
of vision, light flashes and
scotoma.
Typical eye lesions on serial
fundoscopic examination;
discrete patches of retinal
whitening with distinct borders,
spreading centrifugally, often
following blood vessels,
associated with retinal
vasculitis, haemorrhage and
necrosis.
Definitive diagnosis
Definitive diagnosis required for
other sites. Symptoms and signs
of other organ involvement,
e.g. pneumonitis, pancreatitis,
colitis, cholecystitis, not
responding to co-trimoxazole
or antibiotics. Histology. CSF
polymerase chain reaction
(PCR).
CNS toxoplasmosis
Fever, headache, focal
neurological signs, convulsions.
Rapid response (within 10
days) to high-dose
co-trimoxazole, or
pyrimethamine and
sulphadiazine or clindamycin.
Not required but confirmed by
computed tomography (CT)
scan showing single/multiple
lesions with mass effect/
enhancing with contrast.
If lumbar puncture (LP)
performed, CSF nonspecific or
normal. Resolution of findings
after treatment if patient
survives.
Cryptococcal meningitis
or other extrapulmonary
Cryptococcus infection
Meningitis: usually subacute,
fever with increasing severe
headache, meningism,
confusion, behavioural changes.
Confirmed by CSF microscopy
(India ink or Gram stain).
Serum or CSF CRAG-positive or
culture-positive.
Responds to antifungal
therapy.
HIV encephalopathy
Clinical finding of disabling
cognitive and/or motor
dysfunction interfering with
activities of daily living,
progressing over weeks or
months in the absence of a
concurrent illness or condition
other than HIV infection which
might explain the findings.
Recommended to confirm
clinical features and exclude
other causes including
neurosyphilis:
• brain scan by means of
CT or magnetic resonance
imaging (MRI) with
• LP.
LP should be conducted to
exclude other infectious causes.
26
Clinical event
Disseminated non-tuberculous
mycobacteria infection
Presumptive diagnosis
No presumptive diagnosis.
Definitive diagnosis
Nonspecific clinical symptoms
including progressive weight
loss, fever, anaemia, night
sweats, fatigue or diarrhoea.
Severe anaemia and/or elevated
alkaline phosphatase and/or
(in case of diarrhoea) persisting
AFB in the stool in spite of TB
therapy.
Plus:
Culture of atypical mycobacteria
species from stool, blood,
body fluid or other body tissue,
excluding lung.
PML
No presumptive diagnosis.
Progressive focal neurological
signs without headache or
fever, cortical blindness,
cerebellar signs, dementia.
Confirmed by consistent MRI
or CT scan, and biopsy. Viral
PCR for Jacob Creutzfeldt virus.
Candidiasis of trachea, bronchi, No presumptive diagnosis.
lungs
Confirmed by symptoms,
clinical signs suggestive of
organ involvement and/or
macroscopic appearance at
bronchoscopy. Histology or
cytology, or microscopy of
specimen from tissue.
No presumptive diagnosis.
Cryptosporidiosis (with
diarrhoea lasting more than one
month)
Chronic diarrhoea, often profuse
and watery, with weight loss,
± abdominal pain, nausea,
vomiting; confirmed by modified
ZN microscopic examination
of stool. Stools observed to
be unformed with organism
visualized in stool sample.
Isosporiasis
Watery diarrhoea, cramps and
weight loss. Symptoms usually
indistinguishable from those of
cryptosporidiosis.
No presumptive diagnosis.
Isosporiaisis responds to highdose cotrimoxazole.
27
INTERIM WHO CLINICAL STAGING OF HIV/AIDS AND HIV/AIDS CASE DEFINITIONS FOR SURVEILLANCE
AFRICAN REGION
Clinical event
Presumptive diagnosis
Any disseminated mycosis (e.g. No presumptive diagnosis.
coccidiomycosis, histoplasmosis,
penicilliosis)
Definitive diagnosis
Clinical symptoms nonspecific,
e.g. skin rash, cough, shortness
of breath, fever, anaemia,
weight loss.
CXR: infiltrates or nodules.
Confirmed by direct microscopy.
Histology: usually granuloma
formation. Isolation: antigen
detection from affected
tissue. Skin lesion culture or
microscopy positive.
Recurrent non-typhoidal
salmonella septicaemia (two or
more episodes in last year )
No presumptive diagnosis.
Nonspecific symptoms: fever,
sweats, headaches, weight
loss, diarrhoea and anorexia.
Confirmed by blood culture.
Lymphoma (cerebral or B cell
non-Hodgkin)
No presumptive diagnosis.
Symptoms consistent with
lymphoma: lymphadenopathy,
splenomegaly, pancytopenia,
testicular or lung mass lesions;
no response clinically to
antitoxoplasma or anti-TB
treatment.
CNS imaging: at least one
lesion with mass effect on brain
scan; histology.
Invasive cervical carcinoma
No presumptive diagnosis.
Persistent vaginal discharge,
postcoital or intermenstrual
bleeding unresponsive to
appropriate antibacterial or
antifungal treatment; cervical
lesions visualized. Histology.
Cytology, but not carcinoma
in situ.
Visceral leishmaniasis
No presumptive diagnosis.
Suggestive symptoms:
malaise, chronic fever,
hepatosplenomegaly,
pancytopenia . Amastigotes
visualized or cultured from any
appropriate clinical specimen.
28
CLINICAL STAGING EVENTS AS A TOOL TO GUIDE
CLINICAL MANAGEMENT IN ADULTS AND ADOLESCENTS
( PRE-ART AND ART FOLLOW-UP CARE)
The same criteria for presumptive and definitive diagnosis apply
Clinical events pre-ART
Action
Stage 1
No action required
Stage 2
Requires cotrimoxazole
Stage 3
Requires cotrimoxazole if not already started
Or
Consider ART
Stage 4
First ever occurrence of a stage 3 or 4 event requires notification
for surveillance purposes
Clinical events on ART
Action
Stage 1
Consider interruption of cotrimoxazole if stable on ART for
6 months or more.
New or recurrent :
Check adherence
Stage 2
Treat and manage condition
or
Restart cotrimoxazole
stage 3
Should alert the provider to the possibility of poor adherence or
failing response to treatment.
New or recurrent
Check adherence
Stage 4
Treat and manage condition
Restart cotrimoxazole
Consider regimen switch
Suggest failure to respond to ART, possibly because of true failure
of the regimen and/or poor adherence.
29
INTERIM WHO CLINICAL STAGING OF HIV/AIDS AND HIV/AIDS CASE DEFINITIONS FOR SURVEILLANCE
AFRICAN REGION
ANNEX 2.
WHO CLINICAL STAGING FOR INFANTS AND CHILDREN :
PRESUMPTIVE AND DEFINITIVE CRITERIA FOR RECOGNIZING
HIV/AIDS-RELATED CLINICAL EVENTS
(For use in infants and children aged under 15 years with laboratory evidence of HIV infection: HIV
antibody in those aged 18 months and above, DNA or RNA virological testing or P24 antigen testing
for those aged under 18 months.)
Highlighted events are still awaiting further data for clarification of definitions
Clinical event
Clinical diagnosis
Definitive diagnosis
Clinical Stage 1
Asymptomatic
No symptoms reported and no
signs on examination.
Not required.
PGL
Swollen or enlarged lymph
nodes >1 cm at two or more
non-contiguous sites, without
known cause.
Not required.
(Histology; germinal centre
hyperplasia, lymph node
structure preserved.)
Hepatosplenomegaly
Unexplained enlarged liver or
spleen.
Not required.
Papular pruritic eruptions
Persistent papular pruritic
vesicular lesions; scabies
should be excluded.
Not required.
Seborrhoeic dermatitis
Itchy scaly skin condition
Not required.
particularly affecting scalp, face,
upper trunk and perineum. Also
common in uninfected children
and in babies.
Fungal nail infections
Fungal paronychia (painful,
red and swollen nail bed)
or onycholysis (painless
separation of the nail from
the nail bed). Proximal white
subungual onchomycosis
is uncommon without
immunodeficiency.
Clinical Stage 2
Culture of nail scrape.
30
Clinical event
Clinical diagnosis
Definitive diagnosis
Angular cheilitis
Splits or cracks on lips at
the angle of the mouth with
depigmentation, usually
responding to antifungal
treatment but may recur.
Also common in nutritional
deficiency, e.g. of B vitamins.
Not required.
LGE
Erythematous band that
follows the contour of the
free gingival line; may be
associated with spontaneous
bleeding.
Not required.
Uncommon in HIV-uninfected
children.
Not required.
Human papilloma virus infection Characteristic skin lesions;
(extensive facial, more than 5% warts; small fleshy grainy
of body area or disfiguring)
bumps, often rough, on sole of
feet are flat (plantar warts).
Also common in uninfected
children.
Molluscum contagiosum
infection
(extensive facial, more than 5%
of body area or disfiguring)
Characteristic skin lesions:
small flesh-coloured, pearly
or pink, dome-shaped or
umbilicated growths, may be
inflamed or red.
Not required.
Also common in uninfected
children.
Recurrent oral ulcerations
(two or more in six months)
Aphthous ulceration,
Not required.
typically with a halo of
inflammation and a yellow-grey
pseudomembrane.
Parotid enlargement
Asymptomatic bilateral swelling Not required.
that may spontaneously resolve
and recur, in absence of other
known cause, usually painless.
Uncommon in HIV-uninfected
children.
31
INTERIM WHO CLINICAL STAGING OF HIV/AIDS AND HIV/AIDS CASE DEFINITIONS FOR SURVEILLANCE
AFRICAN REGION
Clinical event
Herpes zoster
Clinical diagnosis
Definitive diagnosis
Painful rash with fluidViral culture, histology, EM of
filled blisters, dermatomal
lesion fluid.
distribution, can be
haemorrhagic on erythematous
background, and can become
large and confluent. Does not
cross the midlines. Note: severe
persistent herpes zoster may
have worse prognosis.
Recurrent RTI
Symptom complex, e.g. fever
(twice or more in any six-month with unilateral face pain and
period)
nasal discharge (sinusitis)
or painful swollen eardrum
(otitis media), sore throat with
productive cough ( bronchitis),
sore throat (pharyngitis) and
barking croup-like cough (LTB).
Persistent or recurrent ear
discharge.
Not required but may be
confirmed by laboratory or
X-ray studies where available,
especially for sinus, and culture
or appropriate specimens.
Clinical Stage 3
Unexplained moderate
malnutrition (very low weightfor-age: up to −2 standard
deviations (SDs) (3, 4) ; not
responding adequately to
standard therapy,
Unexplained weight loss
or failure to gain weight
not explained by poor or
inadequate feeding or other
infections , and not adequately
responding within two weeks
to standard management ,
Documented loss of body
weight, failure to gain weight
on standard management and
no other cause identified during
investigation.
Unexplained persistent
diarrhoea
(14 days and above)
Unexplained persistent
diarrhoea (loose or watery
stool, three or more times
daily), not responding to
standard treatment.
Not required, but confirmed
if stools observed and
documented as unformed.
Culture and microscopy reveal
no pathogens.
Unexplained persistent fever
(intermittent or constant and
for longer than one month)
Reports of fever or night
sweats for longer than one
month, either intermittent or
constant, with reported lack
of response to antibiotics or
antimalarials.
Not required but confirmed if
documented fever of >37.5 °C
with negative blood culture,
negative malaria slide and
normal or unchanged CXR,
and no other obvious foci of
disease.
No other obvious foci of
disease reported or found on
examination. Malaria must be
excluded in malarious areas.
32
Clinical event
Clinical diagnosis
Definitive diagnosis
Oral candidiasis
(outside first 6 weeks of live)
Persistent creamy white to
Microscopy or culture.
yellow soft small plaques
on red or normally coloured
mucosa, easily scraped off
(pseudomembranous), or red
patches on tongue, palate
or lining of mouth, usually
painful or tender, responding to
antifungal treatment.
Oral hairy leukoplakia
Fine small linear patches on
lateral borders of tongue,
generally bilaterally, which do
not scrape off.
Not required.
Pulmonary TB
Nonspecific symptoms,
e.g. chronic cough, fever,
night sweats, anorexia and
weight loss. In the older child
also productive cough and
haemoptysis. Response to
standard anti-TB treatment in
one month.
Abnormal CXR plus positive
sputum smear, or culture.
Note: diagnosis should be
made in accordance with
national guidelines.
Severe recurrent presumed
bacterial pneumonia
Acute necrotizing ulcerative
gingivitis or stomatitis, or
acute necrotizing ulcerative
periodontitis
33
Cough with fast breathing,
chest indrawing, nasal flaring,
wheezing, and grunting.
Crackles or consolidation on
auscultation. Responds to
course of antibiotics.
Not required but confirmed by
Severe pain, ulcerated gingival
papillae, loosening of teeth,
spontaneous bleeding, bad
odour, and rapid loss of bone
and/or soft tissue.
Not required.
isolation of bacteria from
appropriate
clinical specimens.
INTERIM WHO CLINICAL STAGING OF HIV/AIDS AND HIV/AIDS CASE DEFINITIONS FOR SURVEILLANCE
AFRICAN REGION
Clinical event
Symptomatic LIP
Clinical diagnosis
No presumptive clinical
diagnosis.
Definitive diagnosis
CXR: bilateral reticulonodular
interstitial pulmonary infiltrates
present for more than two
months with no response
to antibiotic treatment and
no other pathogen found.
Oxygen saturation persistently
<90%. May present with
cor pulmonale and may have
increased exercise-induced
fatigue.
Frequently confused with
miliary TB.
Chronic HIV-associated
lung disease (including
brochiectasis)
No presumptive clinical
diagnosis.
Unexplained anaemia (< 8g/dl), No presumptive clinical
diagnosis.
and or neutropenia (<500/
mm3) and or thrombocytopenia
(<50 000/ mm3) for longer
than one month
History of cough productive of
copious amounts of purulent
sputum, with or without
clubbing, halitosis, and
crepitations and/or wheezes
on auscultation; CXR may
show honeycomb appearance
(small cysts) and/or persistent
areas of opacification and/or
widespread lung destruction,
with fibrosis and loss of
volume. CT scan of chest may
be used to confirm.
Diagnosed on laboratory
testing, not explained by other
non-HIV conditions, or not
responding to standard therapy
with haematinics, antimalarials
or anthelmintics as outlined in
IMCI.
34
Clinical Stage 4
Clinical event
Unexplained severe wasting
or severe malnutrition not
adequately responding to
standard therapy
Clinical diagnosis
Definitive diagnosis
Documented loss of weight or
Persistent weight loss not
explained by poor or inadequate failure to gain weight.
feeding, other infections and
not adequately responding in
two weeks to standard therapy.
Characterized by:
visible severe wasting of
muscles, with or without
oedema of both feet, and/or
weight-for-height of –3 SDs, as
defined by WHO IMCI guidelines.
Pneumocystis pneumonia (PCP) Dry cough, progressive
shortness of breath, cyanosis,
tachypnoea and fever; chest
indrawing or stridor. Response
to high-dose co-trimoxazole
+/– prednisolone.
Microscopy of induced sputum
or BAL, or histology of lung
tissue.
CXR shows typical bilateral
perihilar diffuse infiltrates.
(Severe or very severe
pneumonia as in IMCI). Usually
of sudden onset and very
severe in infants under six
months of age .
Recurrent severe presumed
bacterial infection (two or
more episodes in one year),
e.g. meningitis, empyema,
pyomyositis, bone or joint
infection, bacteraemia
Fever accompanied by specific
symptoms or signs that
localize infection. Responds to
antibiotics.
Not required but confirmed
by bacteria isolated from
appropriate clinical specimens
and includes recurrent
non-typhoidal salmonella
septicaemia.
Chronic herpes simplex virus
infection (chronic orolabial or
intraoral lesions of more than
one month or visceral of any
duration)
Severe and progressive painful
orolabial or skin lesions
attributable to recurrent HSV
reported for more than one
month. History of previous
episodes. Scarring from
previous episodes may be
evident.
Visceral HSV requires
confirmation. Suggestive
symptoms of organ damage,
e.g. bronchitis, pneumonitis,
oesophagitis, colitis,
encephalitis, supported by
histology or culture.
35
INTERIM WHO CLINICAL STAGING OF HIV/AIDS AND HIV/AIDS CASE DEFINITIONS FOR SURVEILLANCE
AFRICAN REGION
Clinical event
Clinical diagnosis
Definitive diagnosis
Oesophageal candidiasis
Chest pain and dysphagia
(difficulty in swallowing),
odynophagia (pain on
swallowing food and fluids),
or retrosternal pain worse on
swallowing (food and fluids)
+/– oral Candida. Responds
to antifungal treatment.
May be difficult to detect in
young children. Suspect if oral
Candida observed and if refusal
occurs or if there are difficulties
or crying when feeding.
Not required but confirmed
by macroscopic appearance
at endoscopy, microscopy
of specimen from tissue or
macroscopic appearance at
bronchoscopy or histology.
Extrapulmonary TB
TB not limited to lungs.
Mycobacterium TB isolated
form blood culture or other
specimen except sputum
or BAL. Positive AFB on
microscopy or culture on
relevant specimens.
Systemic illness usually with
prolonged fever, night sweats,
weight loss.
Clinical features of organs
involved, e.g. focal
lymphadenopathy, cold
abscess, sterile pyuria,
pericarditis, ascites, pleural
effusion, meningitis, arthritis,
orchitis, lupus vulgaris.
Biopsy and histology. X-ray.
Responds to standard anti-TB
therapy.
Note: simple lymph gland
extrapulmonary TB may have a
better prognosis.
Kaposi’s sarcoma
Typical red-purple lesions seen
Typical appearance in skin or
oropharynx, initially flat patches on bronchoscopy or endoscopy.
with a pink or blood-bruise
Biopsy.
colour, usually developing into
nodules.
36
Clinical event
Clinical diagnosis
Definitive diagnosis
Symptoms and signs of organ
involvement, e.g. typical eye
lesions on fundoscopy or
pneumonitis not responding to
co-trimoxazole or antibiotics.
Histology or detection of
antigen from affected tissue.
CMV retinitis and CMV
infection of organs other than
liver, spleen or lymph nodes,
with onset at age over 1 month
No presumptive clinical
diagnosis.
CNS toxoplasmosis
(outside the neonatal period )
Fever, headache, focal
neurological signs, convulsions.
Response to high-dose cotrimoxazole or pyrimethamine
and sulphadiazine or
clindamycin.
Cryptococcal meningitis
Meningitis: usually subacute,
CSF: microscopy (India ink or
fever with increasing severe
Gram stain)
headache, irritability,
Positive serum CRAG test.
meningism, confusion,
behavioural changes. Responds
to antifungal therapy
HIV encephalopathy
At least one of the following,
progressing over at least two
months in the absence of
another illness:
Clinically, disease suspected if
there are typical eye lesions on
serial fundoscopic examination;
discrete patches of retinal
whitening with distinct borders,
spreading centrifugally, often
following blood vessels,
associated with retinal vasculitis,
haemorrhage and necrosis.
CT scan showing single/
multiple lesions with mass
effect/enhancing with
contrast. CSF results normal or
nonspecific.
Resolution of findings after
treatment if patient survives.
Brain CT scan or MRI to exclude
other causes.
• gross discrepancy between
the actual and developmental
age, failure to attain, or loss
of, developmental milestones,
loss of intellectual ability;
or
• progressive impaired brain
growth demonstrated
by stagnation of head
circumference;
or
• acquired symmetric motor
deficit accompanied by two
or more of the following:
paresis, pathological reflexes,
ataxia, gait disturbances.
37
INTERIM WHO CLINICAL STAGING OF HIV/AIDS AND HIV/AIDS CASE DEFINITIONS FOR SURVEILLANCE
AFRICAN REGION
Clinical event
Any disseminated mycosis
(e.g. histoplasmosis,
coccidiomycosis, penicilliosis)
Clinical diagnosis
No presumptive clinical
diagnosis.
Definitive diagnosis
Organ-specific and nonspecific
symptoms, e.g. may cause skin
rash, or cough, shortness of
breath, fever, anaemia, weight
loss.
Diagnosis confirmed by direct
microscopy, histology or antigen
detection in relevant specimens.
CXR may show infiltrates or
nodules.
Candidiasis of the trachea,
bronchi or lungs
No presumptive clinical
diagnosis.
Macroscopic appearance at
endoscopy.
Microscopy and culture of
specimen from endoscopic
tissue.
Disseminated mycobacteriosis,
other than TB
No presumptive clinical
diagnosis.
Nonspecific clinical symptoms
including progressive weight
loss, fever, anaemia, night
sweats, fatigue or diarrhoea;
plus
culture of atypical mycobacteria
species from stool, blood,
body fluid or other body tissue,
excluding lung.
Cryptosporidiosis
(with diarrhoea lasting more
than one month)
No presumptive clinical
diagnosis.
Chronic diarrhoea, often
profuse and watery, with
weight loss, ± abdominal pain,
nausea, vomiting, but usually
mild or no fever. Confirmed by
microscopic examination on
modified ZN stain.
Isosporiasis
No presumptive clinical
diagnosis.
Chronic diarrhoea, often
profuse and watery, with
weight loss, ± abdominal pain,
nausea, vomiting. Isosporiasis
responds to high-dose cotrimoxazole.
38
Clinical event
Clinical diagnosis
Cerebral or B cell non-Hodgkin No presumptive clinical
lymphoma
diagnosis.
Definitive diagnosis
Symptoms consistent with
lymphoma: lymphadenopathy,
hepatosplenomegaly,
pancytopenia, besides other
nonspecific or organ-specific
symptoms. No response
clinically to antitoxoplasma or
anti-TB treatment.
CNS imaging: at least one
lesion with mass effect on
brain scan, and no response
to antitoxoplasma and anti-TB
treatment. Cytology. Histology.
Response to chemotherapy.
PML
No presumptive clinical
diagnosis.
Acquired HIV-associated rectal
fistula, including rectovaginal
fistula
39
Progressive focal neurological
signs without headache or
fever. Cortical blindness and
cerebellar signs. Convulsions
are rare. MRI or CT scan
Further information and
evidence relating to this
condition and its definition are
being sought. Case reports from
African countries suggest that it
is highly specific to HIV and that
the prognosis is poor. Clinical
features suggestive, exclusion of
other causes, faecal discharge
through the vagina or urethra,
or urine discharge through the
rectum in an HIV-infected child
usually following an episode of
diarrhoea.
INTERIM WHO CLINICAL STAGING OF HIV/AIDS AND HIV/AIDS CASE DEFINITIONS FOR SURVEILLANCE
AFRICAN REGION
Clinical event
HIV-associated nephropathy
Clinical diagnosis
No presumptive clinical
diagnosis.
HIV-associated cardiomyopathy No presumptive clinical
diagnosis.
Definitive diagnosis
Further information and
evidence relating to this
condition and its definition
are being sought. Symptoms
and signs suggestive of renal
disease, with no other obvious
cause identified. Early morning
urine protein/creatinine ratio
of >200mg/mmol in absence
of a urinary tract infection
and absence of an axillary
temperature of 38.0 ºC. Renal
biopsy and histology.
Further information and
evidence relating to this
condition and its definition are
being sought. Exclusion of other
causes of congestive cardiac
failure. The left ventricle and
right ventricle are enlarged. The
end-diastolic and end-systolic
dimensions of the left or right
ventricle are increased (2 SDs
from the mean for body surface
area), with a reduced fractional
shortening and ejection
fraction (2 SDs from the mean).
Echocardiography check.
40
CLINICAL STAGING EVENTS AS A TOOL TO GUIDE
CLINICAL MANAGEMENT FOR INFANTS AND CHILDREN
( PRE-ART AND ART FOLLOW-UP CARE)
The same criteria for presumptive and definitive diagnosis apply
Clinical events pre-ART
Action
Stage 1
May require cotrimoxazole
Stage 2
Requires cotrimoxazole
Stage 3
Requires cotrimoxazole if not already started
Or
Consider ART
stage 4
Notification for surveillance purposes of first ever occurrence of
a stage 3 or 4 event.
Clinical events on ART
Action
Stage 1
Currently not advised to discontinue cotrimoxazole in children
under 5 years.
New or recurrent :
Check adherence, provide support
Stage 2
Treat and manage condition
or
stage 3
Should alert the provider to the possibility of poor adherence or
failing response to treatment.
New or recurrent
Check adherence, provide support
Stage 4
Treat and manage condition
Consider ART regimen switch
Suggests failure to respond to ART, possibly because of true
failure of the regimen and/or poor adherence.
41
INTERIM WHO CLINICAL STAGING OF HIV/AIDS AND HIV/AIDS CASE DEFINITIONS FOR SURVEILLANCE
AFRICAN REGION
KEY REFERENCES
1.
http://www.who.int/hiv/strategic/surveillance/definitions/en/
2.
http://www.who.int/3by5/publications/documents/arv_guidelines/en/
3.
http://www.who.int/child-adolescent-health/publications/child_health/who_fch_
cah_00.1.htm
4.
http://www.who.int/nut/documents/manage_severe_malnutrition_eng.pdf
5.
Oral Manifestations of HIV in the Developing and Developed World. Proceedings
and abstracts of the 4th International Workshop on Oral Manifestations of HIV
Infection. Oral Dis. 2002; 8 Suppl 2:6-8.
6.
Mortality of infected and uninfected infants born to HIV-infected mothers in Africa:
a pooled analysis. The Lancet 2004; 364:1236-1243. Marie Louise Newell, Hoosen
Coovadia, Marjo Cortina-Borja, Nigel Rollins, Philippe Gaillard & Francois Dabis.
Available at :
http://www.thelancet.com/journals/lancet/article/PIIS0140673604171407/fulltext
7.
Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected
Zambian children (CHAP): a double-blind randomized placebo-controlled trial
C Chintu b, GJ Bhat b, AS Walker a, V Mulenga b, F Sinyinza b, K Lishimpi b, L
Farrelly , N Kaganson , A Zumla , SH Gillespie , AJ Nunn and DM Gibb on behalf of
the CHAP trial team. Available at:
http://www.thelancet.com/journals/lancet/article/PIIS0140673604174424/fulltext
8.
PENTA guidelines for the use of antiretroviral therapy, 2004 M Sharland,
S Blanche, G Castelli, J Ramos and DM Gibb on behalf of the PENTA Steering
Committee. Available at http://www.ctu.mrc.ac.uk/penta/guidelin.pdf
9.
US The Working Group on Antiretroviral Therapy and Medical Management of
HIV-Infected Children.Guidelines for the Use of Antiretroviral Agents in Pediatric
HIV Infection .March 24, 2005. Available at: http://aidsinfo.nih.gov/guidelines/
default_db2.asp?id=51
42
For more information, contact:
WORLD HEALTH ORGANIZATION
Department of HIV/AIDS
20, avenue Appia
CH-1211 Geneva 27
Switzerland
E-mail: [email protected]
http://www.who.int/hiv/en